ML15085A048: Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
(Created page by program invented by StriderTol)
Line 15: Line 15:


=Text=
=Text=
{{#Wiki_filter:UNIVERSITY of MISSOURIRESEARCH REACTOR CENTERMarch 18, 2015Mr. Steve LynchU.S. Nuclear Regulatory Commission Office of Nuclear Reactor Regulation Division of Policy and Rulemaking, Research and Test Reactors Licensing Office: 0-12F08; Mail Stop: 0-12D20Washington DC 20555-0001
{{#Wiki_filter:UNIVERSITY of MISSOURI RESEARCH REACTOR CENTER March 18, 2015 Mr. Steve Lynch U.S. Nuclear Regulatory Commission Office of Nuclear Reactor Regulation Division of Policy and Rulemaking, Research and Test Reactors Licensing Office: 0-12F08; Mail Stop: 0-12D20 Washington DC 20555-0001


==Dear Mr. Lynch:==
==Dear Mr. Lynch:==
The purpose of this letter is to request a meeting with appropriate NRC staff. The objective ofthe meeting is to provide a technical overview of the recently announced molybdenum 99 projectusing General Atomics proprietary selective gaseous extraction technology and the University ofMissouri Research Reactor (MURR). We envision this meeting requiring several hours topresent information and respond to questions.
The purpose of this letter is to request a meeting with appropriate NRC staff. The objective of the meeting is to provide a technical overview of the recently announced molybdenum 99 project using General Atomics proprietary selective gaseous extraction technology and the University of Missouri Research Reactor (MURR). We envision this meeting requiring several hours to present information and respond to questions.
Representatives from MURR as well as GeneralAtomics and Nordion Medical will participate in presenting the technical overview.
Representatives from MURR as well as General Atomics and Nordion Medical will participate in presenting the technical overview.While this project is currently in the conceptual design stage, we wish to begin dialogue with NRC staff to help assure the efficiency of the regulatory licensing process. We anticipate this project will require a license amendment to our Reactor License (Class 104c Amended Facility License No. R-103, Docket No. 50-186).Your consideration of this request and a response at your earliest convenience would be appreciated.
While this project is currently in the conceptual design stage, we wish to begin dialogue withNRC staff to help assure the efficiency of the regulatory licensing process.
Sincerely, Ralph A. Butler Executive Director University of Missouri Research Reactor Center v 1513 Research Park Drive Columbia, MO 65211 Phone: 573-882-4211 Fax: 573-882-6360 Web: www.murr.missouri.edu Fighting Cancer with Tomorrow's Technology}}
We anticipate thisproject will require a license amendment to our Reactor License (Class 104c Amended FacilityLicense No. R-103, Docket No. 50-186).Your consideration of this request and a response at your earliest convenience would beappreciated.
Sincerely, Ralph A. ButlerExecutive DirectorUniversity of Missouri Research Reactor Centerv1513 Research Park Drive Columbia, MO 65211 Phone: 573-882-4211 Fax: 573-882-6360 Web: www.murr.missouri.edu Fighting Cancer with Tomorrow's Technology}}

Revision as of 06:35, 9 July 2018

University of Missouri Research Reactor - Request for Public Meeting on General Atomics Molybenum-99 Project
ML15085A048
Person / Time
Site: University of Missouri-Columbia
Issue date: 03/18/2015
From: Butler R A
Univ of Missouri - Columbia
To: Lynch S T
Division of Policy and Rulemaking
References
Download: ML15085A048 (1)


Text

UNIVERSITY of MISSOURI RESEARCH REACTOR CENTER March 18, 2015 Mr. Steve Lynch U.S. Nuclear Regulatory Commission Office of Nuclear Reactor Regulation Division of Policy and Rulemaking, Research and Test Reactors Licensing Office: 0-12F08; Mail Stop: 0-12D20 Washington DC 20555-0001

Dear Mr. Lynch:

The purpose of this letter is to request a meeting with appropriate NRC staff. The objective of the meeting is to provide a technical overview of the recently announced molybdenum 99 project using General Atomics proprietary selective gaseous extraction technology and the University of Missouri Research Reactor (MURR). We envision this meeting requiring several hours to present information and respond to questions.

Representatives from MURR as well as General Atomics and Nordion Medical will participate in presenting the technical overview.While this project is currently in the conceptual design stage, we wish to begin dialogue with NRC staff to help assure the efficiency of the regulatory licensing process. We anticipate this project will require a license amendment to our Reactor License (Class 104c Amended Facility License No. R-103, Docket No. 50-186).Your consideration of this request and a response at your earliest convenience would be appreciated.

Sincerely, Ralph A. Butler Executive Director University of Missouri Research Reactor Center v 1513 Research Park Drive Columbia, MO 65211 Phone: 573-882-4211 Fax: 573-882-6360 Web: www.murr.missouri.edu Fighting Cancer with Tomorrow's Technology